Kezar Life Sciences delays KZR-261 dose expansion to 2024, still enrolling Cohort 7

Kezar Life Sciences, Inc.

Phase 1 trial of KZR-261 in solid tumors enrolling Cohort 7 (40 mg/m2); no MTD reached yet.
Revised forecast pushes safety/dose escalation data report and dose expansion start to 2024.
Topline data from expansion portion to be reported when available.
Trial evaluates safety, PK/PD, and preliminary anti-tumor activity in locally advanced/metastatic disease.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.